CareCloud Sees Strong Support for Preferred Stock Proposal
SOMERSET, N.J. — CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology, has made notable strides in its proxy vote solicitation aimed at amending its Series A Preferred Stock. The company has successfully secured around 99% of the votes required to back this important proposal.
Voting Process and Participation
At this point, the Company has received strong indications of support from more than 2.97 million shares, which shows they are closing in on the necessary threshold of 3.02 million shares. Investors who want to participate can easily submit their voting instructions through phone calls, the company website, or by mailing back their proxy cards. Additionally, they have the option to attend the Special Meeting in person, following the detailed instructions outlined in their Definitive Proxy materials.
Potential Outcomes of the Proposal
If the Preferred Stock Proposal is approved, holders of the Series A Preferred Stock will gain protections similar to those currently enjoyed by holders of Series B 8.75% Cumulative Redeemable Perpetual Preferred Stock. Furthermore, dividends for Series A Stock will match those of Series B, allowing the company the flexibility to convert Series A shares into common stock based on a predetermined liquidation preference value. This move reflects CareCloud's proactive approach to ensuring both stability and investor confidence.
Importance of Voting Trends
Although the current sentiment is positive, CareCloud understands that future proxy or voting outcomes can be unpredictable. Shareholders who have already cast their votes still have the option to change their decisions if they choose. Importantly, any shares that are not voted will be counted as “no” votes, which could have a significant impact on the final results. Therefore, active engagement from shareholders is essential.
Understanding the Role of Proxy Statements
This announcement provides a snapshot of the vital details regarding CareCloud’s ongoing proxy solicitation. The Definitive Proxy Statement, which has been filed with regulatory bodies, contains essential information that all Series A Preferred Shareholders should review carefully. Complete filings can be accessed on relevant regulatory websites, ensuring transparency and supporting informed decision-making for investors.
About CareCloud
CareCloud is committed to driving innovation in healthcare management. Their extensive suite of technology-enabled solutions aims to improve both the operational and financial performance of healthcare providers. With a focus on alleviating administrative burdens and enhancing patient care, over 40,000 providers rely on CareCloud’s services, which cover various aspects of practice management and revenue cycle management. Explore their wide range of offerings, including practice management, electronic health records, patient experience solutions, and more on their official website.
Frequently Asked Questions
What is the current voting status for CareCloud’s proposal?
CareCloud has currently secured approximately 99% of the required votes and is nearing the necessary threshold of 3.02 million shares.
What happens if the proposal is approved?
If approved, holders of Series A Preferred Stock will enjoy similar protections as those who hold Series B Preferred Stock and will be able to receive dividends aligned with Series B stock.
How can shareholders participate in the voting process?
Shareholders can participate by calling the provided number, visiting the designated website, or returning their completed proxy cards to CareCloud.
Can shareholders change their votes after submission?
Yes, shareholders have the ability to change their voting instructions after submitting their initial votes.
What is the long-term vision for CareCloud?
CareCloud aims to innovate continually within the healthcare sector, enhancing service delivery and operational efficiency for health practices while improving overall patient experiences.
